Pralidoxime Iodide Cas 94 63 3

Pralidoxime Iodide Cas 94 63 3 Specification

State
Powder

Product Name
Pralidoxime Iodide

Properties
Molecular Formula: C H IN OMolecular Weight: 264.06 g/molMelting Point: Typically 220 C to 225 CAppearance: White to light-yellow/red crystalline powderSolubility: Soluble in water (approx. 13.45 mg/mL), soluble in methanol and DMSO; insoluble in nonpolar solvents.Storage Requirements: Temperature-sensitive and needs to be stored refrigerated (0 to 10 C) or at -20 C under an inert gas

Color
WHITE

Active Ingredient
Pralidoxime Iodide is an active pharmaceutical ingredient (API) primarily used as an antidote in emergency medicine. Also known by its chemical name 2-Pyridine Aldoxime Methiodide (2-PAM), it serves as a critical cholinesterase reactivator

Purity(%)
99.9

CAS No
94-63-3

Molecular Formula
C H IN O

Pralidoxime Iodide Cas 94 63 3 Trade Information

Minimum Order Quantity
25 Kilograms

FOB Port
NAHVA SHEVA

Payment Terms
Cash in Advance (CID), Cash Advance (CA)

Supply Ability
1000 Kilograms Per Day

Delivery Time
3 Days

Packaging Details
BAG

Main Export Market(s)
Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa

Main Domestic Market
All India

Certifications
ALL

About Pralidoxime Iodide Cas 94 63 3

Pralidoxime iodide (also known as 2-PAM iodide) is an oxime-class antidote used in emergency medicine to treat organophosphate poisoning and nerve agent exposure. It works by reactivating the acetylcholinesterase enzyme, which restores normal muscle and nerve function. It is typically administered alongside atropine

How it works: Organophosphates bind to and inactivate acetylcholinesterase, leading to a dangerous buildup of the neurotransmitter acetylcholine. Pralidoxime breaks this bond, allowing the enzyme to function properly again.
Window of opportunity: It is most effective when administered immediately or within 24 hours of exposure. If the organophosphate bond undergoes "aging" (a chemical stabilization process over hours or days), pralidoxime loses its ability to reactivate the enzyme.
Secondary uses: It is also used to treat overdoses of anticholinesterase medications (e.g., ambenonium, neostigmine, and pyridostigmine) commonly prescribed for myasthenia gravis
CAS NO.94-63-3